ISEV 2025 is underway
Excellent conference! Many interesting presentations with extensive clinical data. Excellent backstage discussions! And of course, beautiful Vienna!
Are you working in research or clinical sample analysis and looking for an efficient, simple, and cost-effective method for sEV isolation? Check out our poster explaining how to adapt centrifugation conditions using our online centrifugation calculator (http://vesicles.online) so that sEV isolation on a benchtop centrifuge is as efficient (or even more so!) than other isolation techniques!
And if you're working on protein marker profiling, don't hesitate to try our free and highly sensitive ExoSence FACS kits beta for the detection of CD9/CD81, EpCam, and CD44 on EVs.
We are the winners of call #1 of the Women TechEU program!
We are very proud to be a winner of the Women TechEU program www.womentecheurope.eu ! Exosome Analytics will not only receive a grant, but also customized services that will help us accelerate early-stage clinical studies of our ovarian cancer diagnostic tool!
Study of CD117 abundance on ovarian cancer EVs
We are pleased to inform you that our article "Expression level of CD117 (KIT) on ovarian cancer extracellular vesicles correlates with tumor aggressiveness" is published in Frontiers in Cell and Developmental Biology
In this work, we analyzed the correlation between CD117 expression and the histological type of ovarian tumor.
We have demonstrated that expression of CD117 on tumor cells and its abundance on EVs isolated from cell cultures and body fluids of ovarian cancer patients correlate with tumor type, grade and therapy resistance status. Moreover, using EVs isolated from ovarian cancer ascites, we have shown that recurrent disease is characterized by a much higher abundance of CD117 on EVs than the primary tumor. The results of our pilot study demonstrate that CD117 profiling on EVs could be potentially used in liquid biopsy tests for characterization of aggressivity of ovarian tumors.